CCRM Australia

What CCRM Australia does

CCRM Australia (Centre for Commercialisation of Regenerative Medicine Australia) is an Australian not-for-profit organization that accelerates the translation and commercialisation of regenerative medicine discoveries for Australian researchers and emerging biotechnology companies. Originally established as a non-incorporated joint venture in 2018 and incorporated as a not-for-profit in March 2022, the organization operates from the Australian Regenerative Medicine Institute (ARMI) at Monash University Clayton Campus and serves as the Australian hub within the Global CCRM network, alongside centres in Canada, the Nordics, Israel, Japan, Europe, and Singapore.

Its offering is structured as a suite of programs rather than discrete products: Technology Evaluations assesses commercial viability of novel regenerative medicine technologies; the Attract Unit engages talent, companies, and investment; the Clarity Unit publishes market insights; FundingIP supports funding and intellectual property strategy; the T1D Program targets Type 1 Diabetes translation; and Workshop, Roundtable, and Scientific Symposium programs convene industry, academia, and government stakeholders. Underlying its approach is a commercialization methodology transferred from CCRM Canada — in-licensing, value-adding development, out-licensing, and bundling technologies into spin-outs — adapted for the Australian context.

CCRM Australia's business model is partnership- and grant-driven rather than transactional. The organization engages in direct enterprise partnerships (e.g., strategic advisory for SMSbiotech Australia's Phase 1 trial, co-organized European market entry workshops with INITS, SMART CRC co-development with the University of Queensland) and earns no disclosed revenue from product sales. Specific pricing, headcount, and funding sources are not publicly disclosed, consistent with its not-for-profit structure focused on ecosystem impact rather than commercial monetization.

Name

CCRM Australia

Legal name

Centre for Commercialisation of Regenerative Medicine Australia

Website

https://ccrmaustralia.com.au

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

CCRM Australia is a Melbourne-based not-for-profit that accelerates commercialisation of regenerative medicine discoveries for Australian researchers and biotech companies through partnerships, programs, and its Global CCRM network affiliation.

Ownership category

akta.pro rank

Headquarters

HQ city

Clayton

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CCRM Australia is a not-for-profit organization that accelerates the commercialization of regenerative medicine discoveries in Australia. It delivers strategic partnerships, funding and IP support, advanced manufacturing capabilities for cell and gene therapies, and a coordinated suite of programs (Technology Evaluations, Attract Unit, Clarity Unit, Workshop, Roundtable, Scientific Symposium, FundingIP, and T1D) to move regenerative medicine from bench to bedside. The organization applies a commercialization model adapted from CCRM Canada and operates as part of the Global CCRM network.

Product overview

CCRM Australia operates as a not-for-profit organization that accelerates regenerative medicine commercialization through strategic programs and services. The offering consists of a coordinated suite of programs including Technology Evaluations (for assessing novel technologies), the Attract Unit (for talent and investment engagement), the Clarity Unit (for market insights including AI applications), the Workshop Program (for education on research translation), the Roundtable Program (for stakeholder engagement), the Scientific Symposium Program (for knowledge sharing), FundingIP (for IP and funding support), and the T1D Program (for diabetes-focused research). The organization is modeled on CCRM Canada and is part of the Global CCRM network, leveraging international expertise to support Australian regenerative medicine discoveries from bench to bedside.

Differentiator

Problem solved

Functional benefit

Products and services

• Technology Evaluations

Quantifiable outcome

• Process optimisation on a cell therapy resulting in a 60% reduction in cost of goods (from CCRM Canada)

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Six partnerships are on record, tiered core and flagship.

• SMSbiotechcoreStrategic or Co-development Partner · 4 July 2025Strategic collaboration with SMSbiotech Inc., headquartered in San Diego, to provide strategic and commercial advisory services to its Australian subsidiary SMSbiotech Australia Pty Ltd. SMSbiotech is pioneering advanced therapies through proprietary platform technology spanning multiple therapeutic areas including respiratory disease. The company has a candidate in Phase 1 Clinical Trial in Australia.
• INITScoreStrategic or Co-development Partner · 19 June 2025Partnership with INITS, a dynamic consulting firm supporting biotech companies throughout pharmaceutical development journey. INITS has over 12 years of experience and has supported more than 250 clients in France and internationally. With expertise in biologics (C&GT, EVs, mAbs, proteins), INITS covers CMC, Regulatory, Clinical Supply, Quality Assurance, and Audits. Partnership includes co-organising workshops about internationalising into Europe for clinical trials and commercialisation.
• CCRM NordiccoreStrategic or Co-development Partner · 1 January 2024CCRM Australia maintains continued international collaboration with CCRM Nordic as part of the Global CCRM network.
• University of QueenslandcoreStrategic or Co-development Partner · 1 January 2024Co-development of the SMART CRC (Strategic Research Centres) application with the University of Queensland as part of strategic contributions to major initiatives.
• CCRM (Canada)flagshipStrategic or Co-development Partner · 1 January 2018CCRM Australia was modelled on the highly successful CCRM in Canada and maintains ongoing international collaboration. CCRM has become globally recognised as a translation centre and leading global commercial hub for regenerative medicine and cell therapy since its inception in 2011. The partnership provides access to a demonstrated commercialization model and sector-specific expertise.
• Monash University (ARMI)flagshipStrategic or Co-development PartnerCCRM Australia is located at the Australian Regenerative Medicine Institute (ARMI) at Monash University Clayton Campus. CCRM approached ARMI to establish an Australian 'hub' modelled along the CCRM operational model. This hub is being developed in parallel with other emerging hubs in Israel, Japan, Europe and Singapore.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• BioCurate: BioCurate is an Australian not-for-profit joint venture between Monash and Melbourne universities that commercializes early-stage therapeutic discoveries, directly overlapping CCRM Australia's mandate of moving academic biomedical research toward commercialization in Australia.
• CCRM Nordic: CCRM Nordic is a sister hub within the Global CCRM network offering the same regenerative medicine commercialization and advanced manufacturing model in the Nordics, making it a structurally identical peer.
• Cell and Gene Therapy Catapult: Cell and Gene Therapy Catapult is a UK-based innovation and technology catapult focused on advancing cell and gene therapy commercialization, development, and manufacturing capabilities — a close structural analogue to CCRM Australia's offerings.
• Therapeutic Innovation Australia: Therapeutic Innovation Australia is an Australian NCRIS-enabled infrastructure network providing translational research capabilities to accelerate therapeutic development, operating as a complementary Australian commercialization platform.
• MaRS Discovery District: MaRS is a large Canadian innovation hub supporting commercialization of health and life science ventures; its model of integrating researchers, industry partners, and capital mirrors CCRM Australia's commercialization approach.
• CCRM (Canada): CCRM Canada's Centre for Commercialisation of Regenerative Medicine is the parent model and direct peer; CCRM Australia explicitly applies CCRM Canada's commercialization playbook and benefits from shared global consortium membership.

Broad incumbents

• JLABS (Johnson & Johnson Innovation): JLABS is a global network of biotech incubators operated by Johnson & Johnson Innovation providing lab space, mentorship, and commercialization support to early-stage biotechs — overlapping with CCRM Australia's incubation and acceleration role.
• Innovate UK Catapult Network: The Catapult Network is a UK network of technology and innovation centres supporting commercialization across sectors including cell and gene therapy; its structure mirrors the consortium-style support model CCRM Australia delivers.

Regional players

• MTPConnect: MTPConnect is an Australian Industry Growth Centre for the medical technology, biotechnology, and pharmaceuticals sector, providing similar sector-level commercialization, workforce, and funding support to Australian regenerative medicine initiatives.

Others

• Centre for Drug Candidate Optimisation (Monash): Adjacent Monash-based translational drug development capability; shares the same Monash University ecosystem that hosts CCRM Australia and provides overlapping translational support to Australian biotech discoveries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CCRM_au

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CCRM Australia